311 related articles for article (PubMed ID: 25754473)
1. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
[TBL] [Abstract][Full Text] [Related]
2. A trojan horse for human immunodeficiency virus.
Catuogno S; Esposito CL; de Franciscis V
Chem Biol; 2015 Mar; 22(3):313-4. PubMed ID: 25794434
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras.
Wheeler LA; Trifonova R; Vrbanac V; Basar E; McKernan S; Xu Z; Seung E; Deruaz M; Dudek T; Einarsson JI; Yang L; Allen TM; Luster AD; Tager AM; Dykxhoorn DM; Lieberman J
J Clin Invest; 2011 Jun; 121(6):2401-12. PubMed ID: 21576818
[TBL] [Abstract][Full Text] [Related]
4. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
5. G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates.
Amara A; Vidy A; Boulla G; Mollier K; Garcia-Perez J; Alcamí J; Blanpain C; Parmentier M; Virelizier JL; Charneau P; Arenzana-Seisdedos F
J Virol; 2003 Feb; 77(4):2550-8. PubMed ID: 12551993
[TBL] [Abstract][Full Text] [Related]
6. Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV.
Cordelier P; Morse B; Strayer DS
Oligonucleotides; 2003; 13(5):281-94. PubMed ID: 15000819
[TBL] [Abstract][Full Text] [Related]
7. The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling.
Lin YL; Mettling C; Portalès P; Réant B; Robert-Hebmann V; Reynes J; Clot J; Corbeau P
AIDS; 2006 Jun; 20(10):1369-77. PubMed ID: 16791011
[TBL] [Abstract][Full Text] [Related]
8. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection.
Anderson J; Akkina R
Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795
[TBL] [Abstract][Full Text] [Related]
9. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J; Li H; Zhang J; Piotr S; Rossi J
J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942
[TBL] [Abstract][Full Text] [Related]
10. Evolution of Cell-Type-Specific RNA Aptamers Via Live Cell-Based SELEX.
Zhou J; Rossi JJ
Methods Mol Biol; 2016; 1421():191-214. PubMed ID: 26965267
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 and CCR5 regulation and expression patterns on T- and monocyte-macrophage cell lineages: implications for susceptibility to infection by HIV-1.
Joly M; Pinto JM
Math Biosci; 2005 May; 195(1):92-126. PubMed ID: 15893340
[TBL] [Abstract][Full Text] [Related]
12. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a CCR5-expressing T-lymphoblastoid cell line highly susceptible to R5 HIV type 1.
Baba M; Miyake H; Okamoto M; Iizawa Y; Okonogi K
AIDS Res Hum Retroviruses; 2000 Jul; 16(10):935-41. PubMed ID: 10890354
[TBL] [Abstract][Full Text] [Related]
14. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.
Zhou J; Rossi JJ
BioDrugs; 2012 Dec; 26(6):393-400. PubMed ID: 23046156
[TBL] [Abstract][Full Text] [Related]
16. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1.
Zhou J; Lazar D; Li H; Xia X; Satheesan S; Charlins P; O'Mealy D; Akkina R; Saayman S; Weinberg MS; Rossi JJ; Morris KV
Theranostics; 2018; 8(6):1575-1590. PubMed ID: 29556342
[TBL] [Abstract][Full Text] [Related]
17. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
Bai J; Rossi J; Akkina R
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
[TBL] [Abstract][Full Text] [Related]
18. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
Blanco J; Barretina J; Clotet B; Esté JA
J Leukoc Biol; 2004 Oct; 76(4):804-11. PubMed ID: 15258189
[TBL] [Abstract][Full Text] [Related]
19. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
[TBL] [Abstract][Full Text] [Related]
20. An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro.
Vu JR; Fouts T; Bobb K; Burns J; McDermott B; Israel DI; Godfrey K; DeVico A
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):477-90. PubMed ID: 16796521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
